August 14, 2026

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001.
BSE Scrip Code: 524743

National Stock Exchange of India Ltd.
Exchange Plaza, 5tll floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051.
NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 14th August, 2026

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (14/08/2026):

1. **Financial Results**

Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Period ended 30/06/2026 in the format specified under the SEBI (Listing Obligations and Disclosure Requirements) Regulations ,2015 ('SEBI Listing Regulations"), together with a copy of the Limited Review Reports of M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai for your records. The aforesaid Unaudited Financial Results are also uploaded on the Company's website www.fischermv.com.

An extract of the aforesaid Unaudited Financial Results, in the manner prescribed under the SEBI Listing Regulations, is annexed herewith in **Annexure-1** and the same will be published in English and Telugu newspapers within the time stipulated.

2. **Resignation of Independent Directors**

Noted the Resignation of the Mr. Roberto M Pagdanganan, Independent Director (DIN: 10639820) with effect from the closing hours of 14th August 2026. Details as required under Regulation30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure 2.**

Noted the Resignation of the Mr. Sanjay Jayantilal Jain, Independent Director (DIN: 03162189) with effect from the closing hours of 14th August 2026. Details as required under Regulation30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure 2.**

FISCHER MEDICAL VENTURES LIMITED
(Formerly known as Fischer Chemic Limited)
Registered Office Address: Survey No. 480/2 AP Medtech Zone,
Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032
CIN: L86900AP1993PLC118162
Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548

3. **Reconstitution of Audit Committee and Nomination and Remuneration Committee**

Pursuant to resignation of Independent Directors, the Board has approved the reconstitution of the Committees of the Board. Details as required under Regulation30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure 3.**

4. **Allotment of Equity shares pursuant to conversion of warrants**

The allotment of 2,05,05,909 (Two Crore Five Lakhs Five Thousand and Nine Hundred and Nine) Equity Shares of Re. 1/- (Rupee One only) each at an issue price of Rs. 23.4/- (Rupees Twenty Three and Forty Paise) per share, on preferential basis to the persons of promoters and non-promoter category, in accordance with Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and the provisions of the Companies Act, 2013 and rules made there under as per the list enclosed and marked in **Annexure 4.**

The Board Meeting commenced at 4:30 PM (IST) and concluded at 6:00 PM (IST)

Please take on record.

Thanking You,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

BALAJI GANDLA
Digitally signed by BALAJI GANDLA
Date: 2026.08.14 20:27:53 +05'30'

Fischer Medical Ventures Limited

BALAJI GANDLA

COMPANY SECRETARY AND COMPLIANCE OFFICER

Fischer Medical Ventures Limited
CIN : L86900AP1993PLC118162
STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Amount in INR lakhs)

	Particulars	Quarter ended			Year ended
		June 30, 2026	June 30, 2025	March 31, 2026	March 31, 2026
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
	Income				
I)	**Revenue From Operations**	72.17	454.23	410.76	1,739.18
II)	**Other Income**	89.06	80.40	43.40	349.34
III)	**Total Income (I+II)**	**161.23**	**534.63**	**454.16**	**2,088.52**
	Expenses :				
	Purchase of Traded Goods	75.50	318.59	276.83	1,195.68
	Changes in inventories of finished goods, by-products and work in progres	(7.78)	-	4.58	(35.45)
	Employee Benefit expenses	56.43	41.75	52.39	201.51
	Finance Cost	147.32	130.88	126.55	465.23
	Depreciation and Amortization Expenses	76.74	8.16	43.39	67.86
	Other Expenses	136.00	56.81	967.10	1,244.27
IV)	**Total Expenses (IV)**	**484.22**	**556.19**	**1,470.84**	**3,139.11**
V)	**Profit (Loss) Before exceptional item and tax (III-IV)**	**(322.99)**	**(21.56)**	**(1,016.68)**	**(1,050.58)**
VI)	Exceptional Items	-	-	-	-
VII)	**Profit before tax (V-VI)**	**(322.99)**	**(21.56)**	**(1,016.68)**	**(1,050.58)**
VIII)	Tax Expenses				
	i) Current Tax	-	-	-	-
	ii) Deferred Tax	(27.42)	(39.38)	127.50	17.29
	iii) Tax pertaining to previous year	-	-	(9.00)	(9.00)
IX)	**Profit (Loss) from Continuing Operations (VII-VIII)**	**(350.41)**	**(60.94)**	**(898.18)**	**(1,042.29)**
X)	**Other Comprehensive income;**				
	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or los	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-
	(iv) Income tax relating to items that will be reclassified to profit or los	-	-	-	-
XI)	**Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (IX-X)**	**(350.41)**	**(60.94)**	**(898.18)**	**(1,042.29)**
XII)	Paid up Equity Share Capital (Face Value Re.1/-)	**6,545.15**	**6,485.15**	**6,545.15**	**6,545.15**
XIII)	**Earnings per Equity Shares**				
	1) Basic	**(0.05)**	**(0.01)**	**(0.14)**	**(0.16)**
	2) Diluted	**(0.05)**	**(0.01)**	**(0.13)**	**(0.15)**

Fischer Medical Ventures Limited

Ravindran Govindan
Chairman and Managing Director
DIN: 03137661

NOTES:

1 The unaudited financial results of the Group for the quarter and year ended June 30, 2026 have been prepared in accordance with the Indian Accounting Standards ("Indian Accounting Standards ("Ind As") As Prescribed under section 133 of the Companies Act, 2013 as amended.

2 The unaudited financial results of the Group for the quarter ended June 30, 2026 have been reviewed by the audit committee on August 14, 2026 and thereafter Board of directors at their meeting held on August 14, 2026.

3 The Group is primarily engaged in one business segment in accordance with the requirement of Indian Accounting Standards (Ind As) 108: Operating Segment. Accordingly, no separate segment information has been provided.

4 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.

5 **Subsequent Event**

Subsequent to the reporting period, the Company's Board of Directors, through Circular Resolutions dated August 11, August 12 and August 13 2026, approved the allotment of equity shares upon conversion of convertible warrants, pursuant to the exercise of the conversion option by the respective warrant holders.

The details of the allotments are as follows:

- **11 August 2026:** The Board approved the allotment of 23,00,000 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹4,03,65,000.

- **12 August 2026:** The Board approved the allotment of 66,31,664 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹11,63,85,703.

- **13 August 2026:** The Board approved the allotment of 1,42,78,217 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by persons belonging to the Promoter and Non-Promoter Categories. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹25,05,82,708.35.

Fischer Medical Ventures Limited

Ravindran Govindan
Chairman and Managing Director
DIN: 03137661

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Company') for the quarter ended June 30, 2026 and for the year to date results for the period April 01, 2026 to June 30, 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India, A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bilimoria Mehta & Co,
Chartered Accountants
FRN.: 101490

BILIMORIA MEHTA & CO. ★ FRN: 101490W ★ CHARTERED ACCOUNTANTS

AhmehtA

CA Aakash Mehta
Partner
Membership No: 165824
Place: Mumbai
Date: August 14, 2026
UDIN: 26165824SDGKKR2690

Fischer Medical Ventures Limited
CIN : L86900AP1993PLC118162
CONSOLIDATED STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE30, 2026

(Amount in INR lakhs)

	Particulars	Quarter Ended			Year ended
		June 30, 2026	June 30, 2025	March 31, 2026	March 31, 2026
		Unaudited	Unaudited	Audited	Audited
	Income				
I)	Revenue From Operations	8,192.00	2,344.47	9,753.59	30,857.56
II)	Other Income	148.43	746.64	77.04	1,231.37
III)	**Total Income (I+II)**	**8,340.43**	**3,091.11**	**9,830.62**	**32,088.93**
	Expenses :	-	-	-	-
	Cost of Material Consumed	4,398.12	22.09	6,984.38	11,525.46
	Purchase of Goods	2,209.77	758.01	690.33	8,349.15
	Changes in inventories of finished goods, by-products and work in progress	(786.36)	496.32	(53.55)	(315.59)
	Direct Expenses	-	-	-	-
	Employee Benefit expenses	452.35	316.35	380.87	1,509.42
	Finance Cost	354.30	66.08	366.34	583.40
	Depreciation and Amortization Expenses	136.04	76.97	92.57	297.93
	Other Expenses	793.00	341.41	2,126.79	5,480.78
(IV)	**Total Expenses (IV)**	**7,557.22**	**2,077.24**	**10,587.73**	**27,430.54**
V)	**Profit (Loss) Before exceptional items and tax (III-IV)**	**783.21**	**1,013.87**	**(757.11)**	**4,658.39**
VI)	Exceptional Items	-	-	-	-
VII)	**Profit before tax (V+VI)**	**783.21**	**1,013.87**	**(757.11)**	**4,658.39**
VIII)	**Tax Expenses**				
	i) Current Tax	(242.86)	(441.62)	(833.87)	(1,722.88)
	ii) Deferred Tax	(161.22)	(75.09)	288.77	129.08
	iii) Tax pertaining to previous year	-	-	(9.00)	(9.00)
	iv) Minimum Alternate Tax	-	-	68.55	68.55
IX)	**Profit (Loss) from Continuing Operations (VI+VII)**	**379.13**	**497.16**	**(1,242.66)**	**3,124.14**
X)	**Share of Profit/Loss from Associate**				
	- The Therapy Platform Pte Ltd	-	0.11	(3.25)	(3.87)
	- Bluesim tech pte ltd FS	-	(11.26)	2.17	(18.32)
X)	**Profit for the Period (XIII+XIV)**	**379.13**	**486.01**	**(1,243.74)**	**3,101.95**
XI)	**Other Comprehensive income;**				
	(i) Items that will not be reclassified to profit or loss	-	-	(0.89)	5.43
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-
	(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
XII)	**Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (VIII+XI+XII)**	**379.13**	**486.01**	**(1,244.63)**	**3,107.38**
XVII)	Paid up Equity Share Capital (Face Value Re.1/-)	**6,545.15**	**6,485.15**	**6,545.15**	**6,545.15**
XVIII)	**Earnings per Equity Shares**				
	1) Basic	**0.06**	**0.08**	**(0.19)**	**0.47**
	2) Diluted	**0.05**	**0.07**	**(0.18)**	**0.44**

Fischer Medical Ventures Limited

Ravindran Govindan
Chairman and Managing Director
DIN: 03137661

NOTES:

1 The unaudited financial results of the Group for the quarter and year ended June 30, 2026 have been prepared in accordance with the Indian Accounting Standards ("Indian Accounting Standards ("Ind As") As Prescribed under section 133 of the Companies Act, 2013 as amended.

2 The unaudited financial results of the Group for the quarter ended June 30, 2026 have been reviewed by the audit committee on August 14, 2026 and thereafter Board of directors at their meeting held on August 14, 2026.

3 The Group is primarily engaged in one business segment in accordance with the requirement of Indian Accounting Standards (Ind As) 108: Operating Segment. Accordingly, no separate segment information has been provided.

4 The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.

5 **Change in comparative figures**

The consolidated comparative figures for the quarter ended June 30, 2025 in respect of four foreign subsidiaries namely, (FMV International Ventures PTE Ltd., Fischer Hospitality Sdn. Bhd., FMV Global Innovations PTE Ltd., Pellucid Care Health Innovations Pte Ltd (Formerly known as FMV HealthCare PTE Ltd) and one foreign step-down subsidiary i.e., FMV Technologies Sdn Bhd. were initially considered based on financial information certified by the respective management for the quarter ended June 30, 2025, as these subsidiaries were not material individually or in aggregate for the purpose of quarterly consolidation.

Subsequently, the respective component auditors, while completing the annual audit of these foreign subsidiaries including step down subsidiary, identified and incorporated certain audit adjustments relating to the quarterly financial information of the previous year. These adjustments were made to appropriately reflect the financial information on a quarterly basis and to ensure comparability of the quarterly figures

Further, as stated above, the figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited figures up to nine months of the relevant financial year.

Accordingly, the comparative figures for the quarters ended **June 30, 2025 and March 31, 2026** have been revised in the consolidated financial results.

Details of the revisions, are disclosed below for transparency and to facilitate an appropriate understanding and comparison of the financial information.

(Amount in Lakhs)

Particulars	Quarter Ended June 30, 2025	Quarter Ended March 31, 2026
Sales	-	-19.46
Other Income	-	-50.75
Total Income (A)	**-**	**-70.20**
Cost of Material Consumed	-	518.60
Employee Benefit expenses	0.58	-21.26
Finance Cost	-0.91	5.51
Other Expenses	15.14	-41.26
Total Expenses (B)	**14.81**	**461.60**
Net Profit (A-B)	**-14.81**	**-531.80**

6 **Subsequent Event**

Subsequent to the reporting period, the Company's Board of Directors, through Circular Resolutions dated August 11, August 12 and August 13 2026, approved the allotment of equity shares upon conversion of convertible warrants, pursuant to the exercise of the conversion option by the respective warrant holders.

The details of the allotments are as follows:

- **11 August 2026:** The Board approved the allotment of 23,00,000 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹4,03,65,000.

- **12 August 2026:** The Board approved the allotment of 66,31,664 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹11,63,85,703.

- **13 August 2026:** The Board approved the allotment of 1,42,78,217 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by persons belonging to the Promoter and Non-Promoter Categories. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹25,05,82,708.35.

Fischer Medical Ventures Limited

Ravindran Govindan
Chairman and Managing Director
DIN: 03137661

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended June 30, 2026 and consolidated year to date results for the period April 01, 2026, to June 30, 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1 /44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Mumbai : Corporate Office: 507/508, 5th Floor, INIZIO, Cardinal Gracious Road, Chakala, Andheri (East), Mumbai - 400 099. Tel : +91 22 6697 2111/12/13, 2837 5522/33
Registered Office : Sethna Buildging, 1st Floor, 216, Shamaldas Gandhi Marg (Princess Street), Mumbai - 400 002. Tel : +91-22-2201 4884/6807
New Delhi : 505 Mercantile House Buildging, 15, Kasturba Gandhi Marg, Connaught Place New Delhi - 110 001. Tel : +91-11-43543750/23736049
Kolkata : Ground Floor, Jyotermoyee Buildging, 27/2, Chakrabaria Lane, Kolkata - 700 020 (West Bengal) Tel : +91-9804879857
Website : www.bilimoriamehta.in • Email : admin@bilimoriamehta.com

6. We did not review the interim financial results of subsidiaries included in the Statement, whose financial information reflects year-to-date total revenues of Rs 8,174.36 lakhs and year-to-date total comprehensive Profit of Rs 770.04 lakhs, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate is based solely on the review report of such other auditors.

7. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of Step-down Subsidiary, whose unaudited interim financial result includes the year-to-date revenue of Rs. 525.22 Lakhs, year-to-date net loss after tax of Rs. 35.57 Lakhs, and year-to-date total comprehensive loss of Rs. 35.57 Lakhs, for the quarter ended June 30, 2026 which has not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the Associate, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the statement in respect of matter stated above is not modified with respect to the financial result certified by the management.

   Further, these subsidiaries and an associate, which are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective country and which have been reviewed by the other auditors under International Standards on Review Engagements (ISRE). The Holding Company's management has converted the financial results of such subsidiaries and an associate from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries and an associate is based on the review reports of the other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

   Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

Emphasis of Matter

We draw attention to Note No. 5 to the consolidated financial statements, which describes the revision of the comparative figures for the quarters ended June 30, 2025 and March 31, 2026 in respect of certain foreign subsidiaries. The comparative financial information for the quarter ended June 30, 2025 was initially considered based on financial information provided and certified by the respective management, as the respective subsidiaries were not material individually or in aggregate for the purpose of quarterly consolidation. Further, the figures for the quarter ended March 31, 2026 were considered as balancing figures between the audited annual financial statements and the year-to-date figures reported up to the third quarter.

Subsequently, during the annual audit of the respective foreign subsidiaries, the component auditors identified and incorporated certain audit adjustments relating to the quarterly financial information of the previous year. The revised quarterly financial information, incorporating such audit adjustments, was subsequently provided by the component auditors as part of their review deliverables for Q1 FY 2026-27.

Accordingly, the comparative figures for the aforesaid quarters have been revised in the current consolidated financial statements to reflect the financial information provided by the component auditors. As a result, certain comparative figures previously reported in the consolidated financial statements differ from the corresponding figures presented in the current period. These revisions arise from the incorporation of audit adjustments identified during the subsequent annual audit of the foreign subsidiaries and do not affect the overall annual profit/(loss) or closing reserves of the Group for the previous financial year. A detailed reconciliation is also being disclosed in the Note No.5 of the consolidated financials.

Our conclusion is not modified in respect of this matter.

For Bilimoria Mehta & Co,
Chartered Accountants
ICAI Firm Registration No.: 101490W

A.mehta

BILIMORIA MEHTA & CO. FRN: 101490W CHARTERED ACCOUNTANTS

CA Aakash Mehta
Partner
Membership No: 165824
Place: Mumbai
Date: August 14, 2026
UDIN: 26165824HPKGEH6126

ANNEXURE-1

List of Entities included in the statement:

Sr no	Particulars	Stakes	Status	Auditor
1	Time Medical International Ventures (India) Private Limited	100%	Subsidiary	Reviewed by SMPB & Co.
2	Time Medical Philippines (Subsidiary of Time Medical International Ventures (India) Private Limited)	75%	Subsidiary	Reviewed by SMPB & Co.
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of (Time Medical)	Reviewed by SMPB & Co.
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of (Time Medical)	Reviewed by SMPB & Co.
5	Flynncare HealthCare Innovations Private Limited	100%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by SMPB & Co.
6	Wondertech Medical Solutions Pvt Ltd	51%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by SMPB & Co.
7	Nanyang Biologics (India) Private Limited	51%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by SMPB & Co.
8	Fischer Hospitality Sdn. Bhd.	60%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by GW & Co.
9	FMV International Ventures PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by LL Ong & Co.
10	FMV Global Innovations PTE Ltd	100%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by LL Ong & Co.
11	FMV Technologies Sdn Bhd	100%	Step- down subsidiary of Fischer Medical Ventures Limited	Reviewed by GW & Co.
12	PellucidCare Health Innovations Pte Ltd (Formerly known as FMV HealthCare PTE Ltd)	100%	Step- down subsidiary of Fischer Medical Ventures Limited	Reviewed by LL Ong & Co.
13	PT Fischer Pariko Medical Ventures	70%	Step- down subsidiary of Fischer Medical Ventures Limited	Unaudited

FISCHER MEDICAL VENTURES LIMITED
CIN: L86900AP1993PLC118162

Regd Off: No.480/2, Andhra Pradesh Medtech Zone Limited, Nadapura Village, Pedagantyada Mandal, Visakhapatnam, Andhra Pradesh, India, 530044
Corp off: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006, India
Email: cs@fischermv.com | Website: www.fischermv.com

Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30.06.2026 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

Rs. In Lakhs

SL NO	PARTICULARS	STANDALONE				CONSOLIDATED			
		Quarter Ended			Year Ended	Quarter Ended			Year Ended
		30.06.2026	31.03.2026	30.06.2025	31.03.2026	**30.06.2026**	31.03.2026	30.06.2025	31.03.2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	**(Unaudited)**	(Audited)	(Unaudited)	(Audited)
I	**Revenue From Operations**	**72.17**	410.76	454.23	1,739.18	**8,192.00**	9,753.59	2,344.47	30,857.56
II	**Other Income**	**89.06**	43.40	80.40	349.34	**148.43**	77.04	746.64	1,231.37
III	**Total Income (I + II)**	**161.23**	454.16	534.63	2,088.52	**8,340.43**	9,830.62	3,091.11	32,088.93
IV	Expenses								
	Cost Of Materials Consumed	-	-	-	-	**4,398.12**	6,984.38	22.09	11,525.46
	Purchase of Traded Assets	**75.50**	276.83	318.59	1,195.68	**2,209.77**	690.33	758.01	8,349.15
	Changes in inventories of finished goods, by-products and work in progress	**(7.78)**	4.58	-	(35.45)	**(786.36)**	(53.55)	496.32	(315.59)
	Employee Benefits Expense	**56.43**	52.39	41.75	201.51	**452.35**	380.87	316.35	1,509.42
	Depreciation and Amortisation Expenses	**76.74**	43.39	8.16	67.86	**136.04**	92.57	76.97	297.93
	Finance Costs	**147.32**	126.55	130.88	465.23	**354.30**	366.34	66.08	583.40
	Other Expenses	**136.00**	967.10	56.81	1,244.27	**793.00**	2,126.79	341.41	5,480.78
	Total Expenses	**484.22**	1,470.84	556.19	3,139.11	**7,557.22**	10,587.74	2,077.24	27,430.55
V	**Profit / (Loss) Before Exceptional Items & Tax (III - IV)**	**(322.99)**	(1,016.68)	(21.56)	(1,050.58)	**783.21**	(757.11)	1,013.87	4,658.38
VI	**Share of profit/(loss) of Associates**	-	-	-	-		(1.08)	(11.15)	(22.19)
VI	**Exceptional Items**	-	-	-	-	-	-	-	-
VII	**Profit / (Loss) Before Tax (V - VI)**	**(322.99)**	(1,016.68)	(21.56)	(1,050.58)	**783.21**	(758.19)	1,002.72	4,636.19
VIII	Tax Expense								
	Current Tax	-	(9.00)	-	(9.00)	**(242.86)**	(842.87)	(441.62)	(1,731.88)
	Deferred Tax (Asset) / Liability	**(27.42)**	127.50	(39.38)	17.29	**(161.22)**	357.32	(75.09)	197.63
IX	**Profit / (Loss) For The Period From Continuing Operations (VII - VIII)**	**(350.41)**	(898.18)	(60.94)	(1,042.29)	**379.13**	(1,243.74)	486.01	3,101.95
X	**Profit / (Loss) From Discontinued Operations**	-	-	-	-	-	-	-	-
XI	**Tax Expense Of Discontinued Operations**	-	-	-	-	-	-	-	-
XII	**Profit / (Loss) From Discontinued Operations After Tax (X - XI)**	-	-	-	-	-	-	-	-
XIII	**Profit / (Loss) For The Period (IX + XII)**	**(350.41)**	(898.18)	(60.94)	(1,042.29)	**379.13**	(1,243.74)	486.01	3,101.95
XIV	**Items That Will Not Be Reclassified To Profit / (Loss)**								
	(i) Remeasurement of Defined Benefit Plan - Actuarial Gains / (Losses)	-	-	-	-	-	(0.89)		5.43
	(ii) Income Tax Relating On Above	-	-	-	-	-	-	-	-
	(iii) Equity Instruments Through Other Comprehensive Income	-	-	-	-	-	-	-	-
	Other Comprehensive Income - Total	-	-	-	-	-	(0.89)	-	5.43
XV	**Total Comprehensive Income For The Period (Comprising Profit / (Loss) For The Period (After Tax) And Other Comprehensive Income For The Period (After Tax))**	**(350.41)**	(898.18)	(60.94)	(1,042.29)	**379.13**	(1,244.63)	486.01	3,107.38
XVI	**Paid Up Equity Share Capital (Face Value Re.1/-)**	**6,545.15**	6,545.15	6,485.15	6,545.15	**6,545.15**	6,545.15	6,485.15	6,545.15
XVII	**Other Equity**	-			24,684.13				29,309.40
XVIII	**Earnings Per Share (EPS) From Continuing Operations & Discontinued Operations (In Rs.)**	-			-	-			
	Basic	**(0.05)**	(0.14)	(0.01)	(0.16)	**0.06**	(0.19)	0.08	0.47
	Diluted	**(0.05)**	(0.13)	(0.01)	(0.15)	**0.05**	(0.18)	0.07	0.44

Refer Notes attached below

// BY ORDER OF THE BOARD //

For and on behalf of the Board
Fischer Medical Ventures Limited

Fischer Medical Ventures Limited

Chairman & Managing Director
DIN : 03137661

Date: 14.08.2026

ANNEXURE – 2

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. EBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	MR. ROBERTO M PAGDANGANAN	MR. SANJAY JAYANTILAL JAIN
DIN	10639820	03162189
Reason for Change	Resignation as Independent Director of the Company with effect from closure of Business hours on 14th August 2026 due to personal reasons and no other material reasons.	Resignation as Independent Director of the Company with effect from closure of Business hours on 14th August 2026 due to personal reasons and no other material reasons.
Date of cessation	Closure of Business hours on 14th August 2026	Closure of Business hours on 14th August 2026
Term of appointment/reappointment;	Not Applicable	Not Applicable
Brief profile (in case of appointment)	Not Applicable	Not Applicable
Disclosure of relationships between Directors	No relation with Directors	No relation with Directors
Other Directorships / Memberships (in listed entities in case of resignation of Independent director)	Nil	Nil
The independent director shall, along with the detailed reasons, also provide a confirmation that there is no other material reasons other than those provided.	Mr. Roberto M Pagdanganan has confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter.	Mr. Sanjay Jayantilal Jain has confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter.

***

Quezon City
Philippines
30th July 2026

To
The Board of Directors,
FISCHER MEDICAL VENTURES LIMITED,
Survey No. 480/2 AP Medtech Zone, Nadupura Village,
Pedagantyadu Mandal, Pedagantyada,
Visakhapatnam, Andhra Pradesh,
India, 530031.

Subject: Resignation from the position of Independent Director of the Company

Dear Sirs/Madam,

I, Roberto Mamangon Pagdanganan, an Independent Director of Fischer Medical Ventures Limited, hereby tender my resignation from the office with effect from closing business hours on 14th August 2026, due to personal reasons/pre-occupation with other professional commitments.

I confirm that there are no material reasons for my resignation other than those mentioned in this letter.

I take this opportunity to express my sincere gratitude to Chairman Ravindran Govindan, the Board of Directors, the management, and all stakeholders for their support and cooperation during my tenure with the Company. It has been a privilege to serve as an Independent Director, and I wish the Company continued success in all its future endeavors.

Kindly acknowledge receipt of this letter and take the necessary steps to give effect to my resignation, including making the requisite filings and disclosures with the Registrar of Companies and the Stock Exchanges, as applicable.

Thank you and best regards.

Yours faithfully,

Roberto Mamangon Pagdanganan
DIN: 10639820

03rd August 2026

To
The Board of Directors,
FISCHER MEDICAL VENTURES LIMITED,
Survey No. 480/2 AP Medtech Zone, Nadupura Village,
Pedagantyadu Mandal, Pedagantyada,
Visakhapatnam, Andhra Pradesh,
India, 530031.

Subject: Resignation from the position of Independent Director of the Company

Dear Sir/Madam,

I, Sanjay Jayantilal Jain, an Independent Director of Fischer Medical Ventures Limited, hereby tender my resignation from the office of Independent Director with effect from close of business hours on 14th August 2026, due to personal reasons/pre-occupation with other professional commitments.

I confirm that there are no material reasons for my resignation other than those mentioned in this letter.

Kindly acknowledge receipt of this letter and take the necessary steps to give effect to my resignation, including making the requisite filings and disclosures with the Registrar of Companies and the Stock Exchanges, as applicable.

Thanking you.

Yours faithfully,

Sanjay J. Jain

Sanjay Jayantilal Jain
DIN: 03162189

Place: Mumbai

ANNEXURE – 3

Audit Committee:

S no	Name of the Director	Status	Category
1	Mr. Khairy Jamaluddin Abu Bakar	Chairman	Independent Director
2	Ms. Jaya Ankur Singhania	Member	Independent Director
3	Mr. Chan Sing En	Member	Independent Director
4	Dr. Syed Jalaludin	Member	Independent Director
5	Mr. Ravindran Govindan	Member	Executive Director
6	Ms. Svetlana Rao Raviwada	Member	Whole Time Director

Nomination and Remuneration Committee:

S no	Name of the Director	Status	Category
1	Mr. Khairy Jamaluddin Abu Bakar	Chairman	Independent Director
2	Ms. Jaya Ankur Singhania	Member	Independent Director
3	Dr. Syed Jalaludin	Member	Independent Director
4	Mr. Ravindran Govindan	Member	Executive Director

***

ANNEXURE – 4

Details pursuant to Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015.

Sr. No.	**Name of the Allottee**	**Category (Promoter/ Non-promoter)**	**New shares allotted**	**Total Consideration Received (Amount in Rs.)**
1	Shankar Varadharajan	Promoter	60,00,000	10,53,00,000.00
2	FMV Holdings Pte Ltd	Promoter	73,35,909	12,87,45,202.95
3	Roopal Hitesh Kawa	Non-Promoter	71,70,000	12,58,33,500.00

***